Belsomra is not yet available as a generic medication. Its patent exclusivity is anticipated to extend for several more years [1].
When Does Belsomra Patent Protection End?
Belsomra's U.S. patent protection is expected to expire around 2027 [1]. This timeline is subject to change due to potential patent challenges or extensions.
What Does This Mean for Belsomra Pricing?
As long as Belsomra remains under patent protection, it will continue to be sold under its brand name by Merck & Co. The absence of generic competition typically means higher prices for the medication. Once generic versions become available, competition usually leads to a decrease in the cost of the drug.
What is the Difference Between Brand-Name and Generic Drugs?
Brand-name drugs are developed and marketed by pharmaceutical companies that hold patents for them. Generic drugs are bioequivalent versions of brand-name drugs that can be manufactured and sold after the patent expires. They contain the same active ingredients, dosage form, strength, and route of administration as the brand-name drug, but are typically sold at a lower cost [2].
Who Makes Belsomra?
Belsomra (suvorexant) is manufactured by Merck & Co. [1].
What are the Alternatives to Belsomra?
Patients seeking alternatives to Belsomra have several options, including other prescription sleep medications and non-pharmacological approaches. Prescription alternatives may include other sedative-hypnotics like zolpidem (Ambien), eszopiclone (Lunesta), or ramelteon (Rozerem), each with different mechanisms of action and potential side effects. Non-pharmacological approaches, such as cognitive behavioral therapy for insomnia (CBT-I), are also considered effective treatments for chronic insomnia [3].
How Does Belsomra Work?
Belsomra works by blocking the binding of wake-promoting neuropeptides (orexins) to receptors in the brain. By inhibiting the orexin system, Belsomra reduces the drive for wakefulness, thereby promoting sleep [4].
What are the Common Side Effects of Belsomra?
Common side effects reported with Belsomra include drowsiness, dizziness, and somnolence [4].
What is the Clinical Data for Belsomra?
Clinical trials for Belsomra have demonstrated its efficacy in reducing the time it takes to fall asleep and improving sleep maintenance in adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance [4].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration
[3] National Institutes of Health
[4] Belsomra Prescribing Information